Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of COX Inhibition on BP and CBF in Intermittent Hypoxia
NCT01280006Phase 2Completed
- Sponsor
- University of Calgary
- Start
- Jan 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of indomethacin and celecoxib oral solution in obstructive sleep apnea (OSA) and hypertension (HTN) (3 arms), sponsored by University of Calgary. Primary endpoints: Arterial Blood Pressure at Day 5 and Cerebral Blood Flow at Day 5. Started Jan 2011; status: completed.
02
Drugs
indomethacincelecoxib oral solution
03
Conditions
obstructive sleep apnea (OSA)hypertension (HTN)
Beyond the preview
Go deeper on NCT01280006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01280006.